Hirudin and hirudin analogues as new anticoagulant agents
Research article published in Current opinion in hematology (1995)
Abstract
Recombinant hirudin and hirudin analogues constitute interesting new antithrombotic agents that have distinct advantages over heparin. These agents specifically inhibit thrombin and all of its actions and also suppress further thrombin generation. As opposed to unfractionated heparin, hirudin and hirulog effectively suppress clot-bound thrombin, making these agents of particular interest in the treatment of arterial thrombosis, for example, following thrombolysis or percutaneous transthoracic angioplasty. The recent data derived from clinical trials supporting the use of hirudin and hirulog in the prevention and treatment of thrombotic diseases are reviewed here.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Recombinant hirudin and hirudin analogues constitute interesting new antithrombotic agents that have distinct advantages over heparin. These agents specifically inhibit thrombin and all of its actions and also suppress further thrombin generation.
Why This Matters for Hirudotherapy
Relevant to the development and clinical application of leech-derived pharmaceutical compounds.
Citation
Hirudin and hirudin analogues as new anticoagulant agents.
Pineo G, Hull R · Current opinion in hematology, 1995
Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026